文献速递血栓与止血

Efgartigimod(FcRn拮抗剂)治疗成人原发免疫性血小板减少症的2期研究

Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia.
PubMed 文献 · Am J Hematol · 2019-12-10

这项2期研究将38例原发免疫性血小板减少症(ITP)成人患者按1:1:1随机分配,分别接受每周四次静脉输注安慰剂(N=12)、efgartigimod 5 mg/kg(N=13)或10 mg/kg(N=13)。短疗程efgartigimod耐受良好,安全性特征与1期数据一致,可快速降低总IgG水平(较基线平均变化达63.7%),并与具有临床意义的血小板计数升高相关。

要点

  • Efgartigimod短疗程耐受良好,安全性特征与1期数据一致。
  • Efgartigimod使总IgG较基线平均变化达63.7%。
  • Efgartigimod组46%患者至少两次血小板≥50×10^9/L,安慰剂组25%。

核心结论

  • 短疗程efgartigimod在ITP患者中耐受良好,可快速降低总IgG并升高血小板计数,支持进一步评估FcRn拮抗作为ITP新型治疗策略。

研究设计与样本

  • 2期研究,38例成人原发ITP患者按1:1:1随机接受每周四次静脉输注安慰剂(N=12)、efgartigimod 5 mg/kg(N=13)或10 mg/kg(N=13)。

主要发现

  • Efgartigimod使总IgG水平快速降低,较基线平均变化达63.7%。
  • Efgartigimod组46%患者至少两次达到血小板计数≥50×10^9/L,安慰剂组为25%。
  • Efgartigimod组38%患者血小板计数≥50×10^9/L累计至少10天,安慰剂组为0%。
  • Efgartigimod组出血患者比例降低。

临床怎么用

  • 对于既往多线治疗难治的ITP成人患者,可考虑FcRn拮抗劑efgartigimod作为短疗程探索性治疗。

局限性

  • 样本量小(38例),短治疗周期,患者以既往多线治疗难治为主。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Primary immune thrombocytopenia (ITP) is an acquired autoimmune bleeding disorder, characterized by a low platelet count (<100 × 109 /L) in the absence of other causes associated with thrombocytopenia. In most patients, IgG autoantibodies directed against platelet receptors can be detected. They accelerate platelet clearance and destruction, inhibit platelet production, and impair platelet function, resulting in increased risk of bleeding and impaired quality of life. Efgartigimod is a human IgG1 antibody Fc-fragment, a natural ligand of the neonatal Fc receptor (FcRn), engineered for increased affinity to FcRn, while preserving its characteristic pH-dependent binding. Efgartigimod blocks FcRn, preventing IgG recycling, and causing targeted IgG degradation. In this Phase 2 study, 38 patients were randomized 1:1:1 to receive four weekly intravenous infusions of either placebo (N = 12) or efgartigimod at a dose of 5 mg/kg (N = 13) or 10 mg/kg (N = 13). This short treatment cycle of efgartigimod in patients with ITP, predominantly refractory to previous lines of therapy, was shown to be well tolerated, and demonstrated a favorable safety profile consistent with Phase 1 data. Efgartigimod induced a rapid reduction of total IgG levels (up to 63.7% mean change from baseline), which was associated with clinically relevant increases in platelet counts (46% patients on efgartigimod vs 25% on placebo achieved a platelet count of ≥50 × 109 /L on at least two occasions, and 38% vs 0% achieved ≥50 × 109 /L for at least 10 cumulative days), and a reduced proportion of patients with bleeding. Taken together, these data warrant further evaluation of FcRn antagonism as a novel therapeutic approach in ITP.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Newland AC, Sánchez-González B, Rejtő L, et al. Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia. Am J Hematol. 2019. PMID: 31821591. doi:10.1002/ajh.25680

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。